Cargando…
The Impact of Upcoming Treatments in Huntington’s Disease: Resource Capacity Limitations and Access to Care Implications
BACKGROUND: The most advanced disease-modifying therapies (DMTs) in development for Huntington’s disease (HD) require intrathecal (IT) administration, which may create or exacerbate bottlenecks in resource capacity. OBJECTIVE: To understand the readiness of healthcare systems for intrathecally admin...
Autores principales: | Guttman, Mark, Pedrazzoli, Marco, Ponomareva, Marina, Pelletier, Marsha, Townson, Louisa, Mukelabai, Kopano, Levine, Aaron, Nordström, Anna-Lena, Reilmann, Ralf, Burgunder, Jean-Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293639/ https://www.ncbi.nlm.nih.gov/pubmed/33843690 http://dx.doi.org/10.3233/JHD-200462 |
Ejemplares similares
-
Upcoming Meetings Related to Huntington’s Disease
Publicado: (2023) -
Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
por: Saft, Carsten, et al.
Publicado: (2023) -
Pharmacological treatment of chorea in Huntington’s disease–good clinical practice versus evidence-based guideline
por: Reilmann, Ralf
Publicado: (2013) -
International Guidelines for the Treatment of Huntington's Disease
por: Bachoud-Lévi, Anne-Catherine, et al.
Publicado: (2019) -
An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
por: Burgunder, Jean-Marc, et al.
Publicado: (2011)